TWI596095B - Dihydropyridazine-3,5-dione derivatives - Google Patents

Dihydropyridazine-3,5-dione derivatives Download PDF

Info

Publication number
TWI596095B
TWI596095B TW103109058A TW103109058A TWI596095B TW I596095 B TWI596095 B TW I596095B TW 103109058 A TW103109058 A TW 103109058A TW 103109058 A TW103109058 A TW 103109058A TW I596095 B TWI596095 B TW I596095B
Authority
TW
Taiwan
Prior art keywords
group
methyl
trifluoromethyl
phenyl
substituted
Prior art date
Application number
TW103109058A
Other languages
English (en)
Chinese (zh)
Other versions
TW201446756A (zh
Inventor
大竹義仁
岡本直樹
小野芳幸
柏木浩孝
金原篤
原田武雄
堀伸行
村田佳久
橘一生
田中翔太
野村硏一
井出光昭
水口栄作
市田康弘
大友秀一
堀場直
Original Assignee
中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中外製藥股份有限公司 filed Critical 中外製藥股份有限公司
Publication of TW201446756A publication Critical patent/TW201446756A/zh
Application granted granted Critical
Publication of TWI596095B publication Critical patent/TWI596095B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/504Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
TW103109058A 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivatives TWI596095B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013132889 2013-06-25

Publications (2)

Publication Number Publication Date
TW201446756A TW201446756A (zh) 2014-12-16
TWI596095B true TWI596095B (zh) 2017-08-21

Family

ID=51536921

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103109058A TWI596095B (zh) 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivatives
TW106123450A TWI683811B (zh) 2013-03-13 2014-03-13 二氫噠嗪-3,5-二酮衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106123450A TWI683811B (zh) 2013-03-13 2014-03-13 二氫噠嗪-3,5-二酮衍生物

Country Status (29)

Country Link
EP (2) EP3757093A1 (enExample)
JP (2) JP5814488B2 (enExample)
KR (2) KR102072268B1 (enExample)
CN (1) CN105073715B (enExample)
AU (1) AU2014230552B2 (enExample)
BR (1) BR112015022092B1 (enExample)
CA (1) CA2901868C (enExample)
CL (1) CL2015002543A1 (enExample)
CR (1) CR20150505A (enExample)
DK (1) DK2975030T3 (enExample)
ES (1) ES2811126T3 (enExample)
HR (1) HRP20201211T1 (enExample)
HU (1) HUE050577T2 (enExample)
IL (1) IL240825B (enExample)
LT (1) LT2975030T (enExample)
MX (1) MX376532B (enExample)
MY (1) MY174269A (enExample)
NZ (1) NZ711182A (enExample)
PE (1) PE20151535A1 (enExample)
PH (1) PH12015501940A1 (enExample)
PL (1) PL2975030T3 (enExample)
PT (1) PT2975030T (enExample)
RS (1) RS60911B1 (enExample)
RU (1) RU2662832C2 (enExample)
SG (1) SG11201507345RA (enExample)
SI (1) SI2975030T1 (enExample)
TW (2) TWI596095B (enExample)
UA (1) UA118755C2 (enExample)
WO (1) WO2014142273A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ711182A (en) * 2013-03-13 2020-05-29 Chugai Pharmaceutical Co Ltd Dihydropyridazine-3,5-dione derivative
BR112017004595A2 (pt) * 2014-09-12 2017-12-05 Chugai Pharmaceutical Co Ltd composição farmacêutica contendo inibidor de transportador de fosfato dependente de sódio
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料(常州)有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
WO2021261563A1 (ja) 2020-06-26 2021-12-30 日本農薬株式会社 アリールテトラヒドロピリダジン誘導体又はその塩類及び該化合物を含有する殺虫剤並びにその使用方法
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
CA3221186A1 (en) 2021-06-08 2022-12-15 Kenichi Sakai Formulation containing dihydropyridazine-3,5-dione derivative
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
AU2022427156B2 (en) * 2021-12-28 2025-12-11 Nihon Nohyaku Co., Ltd. Aryltetrahydropyridazine derivative or salt thereof and insecticidal agent containing the compound and method for using same
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物
CN116217862A (zh) * 2023-03-21 2023-06-06 中国农业科学院农业环境与可持续发展研究所 一种可降解生物膜助剂的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402580B2 (en) * 2002-02-19 2008-07-22 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
CN102898364A (zh) * 2005-05-18 2013-01-30 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EA017900B1 (ru) * 2006-11-03 2013-04-30 Басф Се Способ получения дифторметилпиразолилкарбоксилатов
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US8217043B2 (en) * 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
EP2565190B1 (en) 2010-04-28 2015-06-03 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827327B2 (ja) * 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
CN103906741B (zh) 2011-10-27 2016-01-20 安斯泰来制药株式会社 氨烷基取代的n-噻吩基苯甲酰胺衍生物
NZ711182A (en) * 2013-03-13 2020-05-29 Chugai Pharmaceutical Co Ltd Dihydropyridazine-3,5-dione derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives

Also Published As

Publication number Publication date
SI2975030T1 (sl) 2020-10-30
BR112015022092A2 (pt) 2017-07-18
TW201446756A (zh) 2014-12-16
AU2014230552A1 (en) 2015-08-13
PE20151535A1 (es) 2015-10-28
HRP20201211T1 (hr) 2020-11-13
SG11201507345RA (en) 2015-10-29
LT2975030T (lt) 2020-09-25
MX2015012537A (es) 2016-02-10
CL2015002543A1 (es) 2016-02-26
PH12015501940B1 (en) 2016-01-11
KR20160119282A (ko) 2016-10-12
JPWO2014142273A1 (ja) 2017-02-16
RU2662832C2 (ru) 2018-07-31
BR112015022092B1 (pt) 2023-04-11
ES2811126T3 (es) 2021-03-10
NZ711182A (en) 2020-05-29
JP6420738B2 (ja) 2018-11-07
HK1212700A1 (zh) 2016-06-17
WO2014142273A1 (ja) 2014-09-18
JP2016040262A (ja) 2016-03-24
CR20150505A (es) 2015-10-26
CN105073715A (zh) 2015-11-18
CN105073715B (zh) 2017-12-01
KR20150127721A (ko) 2015-11-17
MY174269A (en) 2020-04-01
MX376532B (es) 2025-03-07
PL2975030T3 (pl) 2021-01-11
JP5814488B2 (ja) 2015-11-17
CA2901868C (en) 2022-05-03
PH12015501940A1 (en) 2016-01-11
BR112015022092A8 (pt) 2018-01-23
EP2975030B1 (en) 2020-07-15
RU2015143507A (ru) 2017-04-19
HUE050577T2 (hu) 2020-12-28
IL240825B (en) 2020-07-30
KR101664460B1 (ko) 2016-10-10
KR102072268B1 (ko) 2020-01-31
RS60911B1 (sr) 2020-11-30
IL240825A0 (en) 2015-10-29
TWI683811B (zh) 2020-02-01
UA118755C2 (uk) 2019-03-11
DK2975030T3 (da) 2020-08-31
EP2975030A4 (en) 2016-08-03
EP2975030A1 (en) 2016-01-20
AU2014230552B2 (en) 2017-11-16
CA2901868A1 (en) 2014-09-18
PT2975030T (pt) 2020-09-28
TW201741304A (zh) 2017-12-01
EP3757093A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
TWI683811B (zh) 二氫噠嗪-3,5-二酮衍生物
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN105939997B (zh) 作为dlk抑制剂的吡唑衍生物及其用途
CN113321654A (zh) 作为激酶抑制剂的稠合吡啶酮类化合物
CN107072993B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
WO2021190417A1 (zh) 新型氨基嘧啶类egfr抑制剂
CN106661032A (zh) 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物
CN104640865B (zh) 作为激酶抑制剂的二氢吡咯烷子基-嘧啶
CN108779115B (zh) 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
WO2025161532A1 (zh) Pde4b抑制剂及其药物组合物和用途
WO2023274396A1 (zh) 苯并氮杂环类化合物及其在药物中的应用
HK1212700B (en) Dihydropyridazine-3,5-dione derivative
HK1235279B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
HK1235279A1 (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
RU2811864C1 (ru) Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата
WO2026052007A1 (zh) Pde4b抑制剂及其药物组合物和用途